CLINICAL_TRIALS
trial_result
· 2022-01-25
Clinical Trial Update: A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy [Phase 3]
Summary
Phase 3 trial of VX-659 combination therapy for cystic fibrosis was terminated; results posted previously in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2022-01-25